juan ramon retweeted
¿Cambio de paradigma en la cardiología? 🚨
Un nuevo estudio #FLECA-ED desafía un viejo dogma:
☝🏼 En pacientes con fibrilación auricular y enfermedad coronaria estable (sin isquemia activa), la flecainida IV superó a la amiodarona
Mini 🧵 👇🏻
@hrs_journal @secardiologia
juan ramon retweeted
Guarda esta imagen, luego me agradeces.
Si un paciente con FA presenta un ACVi mientras recibe anticoagulación, el riesgo de transformación hemorrágica obliga a suspenderla.
La pregunta de siempre es: ¿cuándo reiniciarla?
Esta gráfica ayuda a responderlo y, en general, favorece el reinicio durante la primera semana especialmente si no existe transformación hemorrágica o no es extensa la isquemia.
juan ramon retweeted
Not all apoB-containing particles tell the same story.
🔹 Non–Lp(a) apoB → greater coronary plaque burden
🔹 Greater relative Lp(a) contribution → more vulnerable plaque features
New in #EJPC: Balance between apoB and Lp(a) may add another layer to cardiovascular risk assessment and personalized prevention. ow.ly/uL2650ZWCIC
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
juan ramon retweeted
What is driving the high burden of CKD in Mexico? #GlobalPerspective highlights need for earlier diagnosis, family screening, standardized risk assessment, and a national registry to improve recognition and outcomes for patients with ADPKD in Mexico. kidney.pub/KID1380 #ASNKidney360
juan ramon retweeted
Interesante
👉Fenotipos de riesgo residual: Características clínicas Comorbilidades
Territorio vascular
➡️Integración terapias basadas en Guiadas por el riesgo residual Equilibrando el beneficio esperado la seguridad, carga del tratamiento y adherencia
tinyurl.com/Integracvd
juan ramon retweeted
#Cholesterol-lowering medicine has changed almost beyond recognition over the past 25 years—from early #statin trials to today's longer-acting, less frequently dosed therapies, some of which may eventually require only one or two doses a year youtube.com/watch?v=atCHnOrY…
#LDL #CVD
juan ramon retweeted
¿Sabías que DXA NO mide «músculo»? 🔬
El mal uso de los términos en composición corporal induce a errores en el diagnóstico de #sarcopenia y #desnutrición.
Por fin,estandarización terminológica en español publicado en authors.elsevier.com/a/1nuuC… 👇🧵 @DrCarlaPrado @irene_breton
juan ramon retweeted
Our work from PREVENT now publ in Circ. Only 37% of FFR neg severe lsns (PB>70% & MLA<4mm2) were lipid-rich plaques (LRP) by NIRS. Event rates were much higher and preventive PCI was only effective in LRPs. PCI of "true vulnerable plaques" may improve prognosis and avoid over-Rx.
juan ramon retweeted
📢 New Review in @LiversMDPI
🧬 Lonardo et al. review liver fibrosis assessment, management, and prevention.
🩺 Fibrosis can regress when the injurious stimulus is controlled, notably at F0–F2.
📖 Read More: brnw.ch/21x6bU8
#LiverFibrosis #Cirrhosis
juan ramon retweeted
STAGE C2D Definition and Management- Critical Stage with Unmet Need! jacc.org/doi/10.1016/j.jchf.… @ShannonMDunlay @preventfailure @FinnGustafsson @SJGreene_md @lamcardio @akshaydesaimd @MG_Crespo_Leiro @dranulala @TheresaMcDonag3 @colleenkmac @NMHheartdoc @spinneymd @laurentrubymd
juan ramon retweeted
Semaglutide mechanisms of action: the missing pieces academic.oup.com/eurheartj/a…
juan ramon retweeted
🔥 It feels foolish to post TWO @rn_flex articles in one day, but here we are.
▪️GREAT REVIEW of the whirlwind that was Tuesday and Wednesday of EASD 2026, plus a pretty great synopsis of how wild the last 10 years have been in GLP-1s
▪️Retatrutide TRIUMPH-1 and -2 and Elora Tirz P1 & T2D P2
▪️If you want to be excited about future treatment *possibilities*, this is a great review of retatrutide and eloralintide + tirzepatide
▪️Caveat: There’s definitely still work to do in optimizing tolerability and safety, and figuring out how to report all of this back to trial readers (docs, investors, and patients)
Humor: Pretty sure there’s a dungeon and dragons/dice-based role playing game reference in there 🤦♀️, plus a classic Jurassic Park one as well 🦕.
[Yes, I’m admitting to playing a weekend or two of D&D in my foolish college years.]
the-incretins.beehiiv.com/p/…
juan ramon retweeted
🤔 ¿A qué hora deben hacer ejercicio los pacientes con Diabetes Tipo 2 (DM2)? Una revisión reciente revela cómo el ritmo circadiano dicta la respuesta metabólica al esfuerzo físico.🧵👇🏻
@SEDiabetes @redGDPS @Diabetes_SEMI @diabeteSEEN
@GT_Pluri_SEMI @SENefrologia
@SLANH_ @PerlaZambrano @drshafikuchay
juan ramon retweeted
EASL–EASD–EASO 2026 MASH guidance: F2–F3, non-cirrhotic disease is the treatment sweet spot.
Semaglutide: obesity/T2D/CV/CKD.
Resmetirom: lean/GLP-1RA-intolerant/atherogenic dyslipidaemia.
journal-of-hepatology.eu/art…
@EASLnews @my_ueg @BritSocGastro
#MASH
juan ramon retweeted
Another important presentation at #EASD2026
- SMARTEST study - register-based randomized trial of #SGLT2i vs metformin in early T2D - no diff in A1c, no diff in complications after mean fu 3.8 yrs. Too early to see a diff perhaps?
uu.se/en/department/medical-…
juan ramon retweeted
En una de las sesiones del #EASD2026 se ha tratado sobre
💢 La amilina en diabetes y obesidad: ¿qué hay de nuevo?
El comentario del Dr. @JoanBarrot del #BlogdeMateu nos sentencia
“LA AMILINA ha llegado para quedarse”
redgedaps.blogspot.com/2026/…
juan ramon retweeted
Our Review now published in @TheLancetEndo
The global diabetes burden is rising particularly in LMICs
Strengthening primary care with multidisciplinary teams, digital pathways and scalable workforce models is key to equitable, person-centred diabetes care.
Thank you @parthaskar & Harini for leading this
sciencedirect.com/science/ar…
@uniofleicester
@ClareHambling
juan ramon retweeted
🔄 A major update in T2D care.
New @ADA_DiabetesPro & @EASDnews 2026 consensus moves beyond glucose: earlier organ protection (SGLT2i, GLP1 based therapies), weight as a core goal, integrated comorbidity care, quality of life & an expanding role for CGM/AID.
👇🏻 🔗
juan ramon retweeted
🆕 Ya está aquí el consenso ADA/EASD 2026 sobre manejo de la diabetes tipo 2 ( regalo de Navidad adelantado 😂)
@AmDiabetesAssn @EASDnews
Pasamos de tratar la glucosa a tratar la enfermedad y sus comorbilidades.
iSGLT2 y/o GLP-1 desde el diagnóstico, con o sin metformina. Combinación precoz si ECV, ERC o IC.
Sin perder el foco en el estilo de vida! 🍎
#EASD2026
diabetesjournals.org/care/ar…
